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Abstract: The stromal vascular cell fraction (SVF) of visceral and subcutaneous adipose tissue (VAT
and SAT) has increasingly come into focus in stem cell research, since these compartments represent
a rich source of multipotent adipose-derived stem cells (ASCs). ASCs exhibit a self-renewal potential
and differentiation capacity. Our aim was to study the different expression of the embryonic stem cell
markers NANOG (homeobox protein NANOG), SOX2 (SRY (sex determining region Y)-box 2) and
OCT4 (octamer-binding transcription factor 4) and to evaluate if there exists a hierarchal role in this
network in ASCs derived from both SAT and VAT. ASCs were isolated from SAT and VAT biopsies
of 72 consenting patients (23 men, 47 women; age 45 ± 10; BMI between 25 ± 5 and 30 ± 5 range)
undergoing elective open-abdominal surgery. Sphere-forming capability was evaluated by plating
cells in low adhesion plastic. Stem cell markers CD90, CD105, CD29, CD31, CD45 and CD146 were
analyzed by flow cytometry, and the stem cell transcription factors NANOG, SOX2 and OCT4 were
detected by immunoblotting and real-time PCR. NANOG, SOX2 and OCT4 interplay was explored by
gene silencing. ASCs from VAT and SAT confirmed their mesenchymal stem cell (MSC) phenotype
expressing the specific MSC markers CD90, CD105, NANOG, SOX2 and OCT4. NANOG silencing
induced a significant OCT4 (70 ± 0.05%) and SOX2 (75 ± 0.03%) downregulation, whereas SOX2
silencing did not affect NANOG gene expression. Adipose tissue is an important source of MSC,
and siRNA experiments endorse a hierarchical role of NANOG in the complex transcription network
that regulates pluripotency.
Keywords: adipose derived stem cell (ASC); regenerative medicine; embryonic stem cell marker network
1. Introduction
Both visceral (VAT) and subcutaneous adipose tissues (SAT) represent an alternative source of
mesenchymal stem cells (MSCs). Adipose-derived stem cells (ASCs) have been proposed by the
International Fat Applied Technology Society as a plastic-adherent, proliferative, multipotent cell
population isolated from adipose tissue [1,2]. ASCs have a fibroblastic-like morphology and possess
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the properties of MSCs traditionally isolated from bone marrow [3,4]. Furthermore, ASCs have
a remarkable potential to differentiate in vitro towards the osteogenic, adipogenic, myogenic and
chondrogenic lineages when maintained under specific culture conditions [5]. Nowadays, there is great
interest in understanding more in detail the cellular and molecular mechanisms of ASCs, which are
known to modulate self-renewal and differentiation properties. Indeed, the latter characteristics
have made it possible to consider them as the preferable candidate for employment in regenerative
medicine [6]. The role of the transcription factors that regulate self-renewal and differentiation is well
known in embryonic stem cells [7]. Boyer et al. showed that OCT4 (octamer-binding transcription
factor 4), NANOG (homeobox protein NANOG) and SOX2 (SRY (sex determining region Y)-box 2)
work as a trio to support each other’s expression and that of other self-renewal genes repressing
differentiation genes [8], while other studies suggested that only OCT4 and NANOG are co-regulated
in embryonic stem cells [7]. However, until today, the exact role of NANOG, OCT4 and SOX2 in adult
stem cells isolated from different tissues has not been well identified and is still controversial [9,10].
For example, knockout of OCT4 did not affect their capacity for colony formation and differentiation
into bone, fat and cartilage [11]. In addition, many studies showed the existence of pseudogenes for
OCT4 [12] and NANOG that are not expressed in the nucleus, but in cytosol [9,13], whose function
has not so far been fully explained. Hyslop et al. suggested that NANOG acts as a gatekeeper of
pluripotency in human embryonic development [14]. In this case, downregulation of NANOG in
human embryonic stem cells (ESCs) induces upregulation of endoderm- and trophectoderm-associated
genes [13–15]. As regards hASCs, the single components of the trio have been described separately,
but the possible interplay among the principal transcription factors has not been fully explored.
Our aim was to study the expression of NANOG, SOX2 and OCT3/4 in ASCs derived from SAT
and VAT and to evaluate whether there exists a transcription factor with a more prominent role in
this network.
2. Results
2.1. Isolation of Adipose Derived Stem Cells
Enzymatic digestion of biopsied human adipose tissue was obtained from 72 consenting patients
(23 men and 47 women; age 45 ± 10 years; with body mass index (BMI) range 25 ± 0.5 and 35 ± 5,
respectively) undergoing elective open-abdominal surgery. The freshly-isolated stromal vascular cell
fraction (SVF) was a compounded cell population with a spindle, triangular, polygonal or round shape,
which contained fibroblasts and adipocytes at different differentiation stages. These cells adhered to a
flask without a substrate. After 48 h, observation under a light microscope showed a round and small
morphology (Figure 1A), whilst after five days (Figure 1B), these cells extended and showed a spindle
shape. After seven days, the number of some mature cells, such as mature adipocytes, decreased,
and the morphology of most cells tended to be uniform. After 10 days (Figure 1C), colonies of
fibroblastic-like cells were observed, although fibroblasts mixed in ASCs were still found. Both of these
cell types reached confluence after about 15 days. MSCs derived from visceral adipose tissue (V-ASCs)
were characterized by large nuclei and elongated cytoplasms (Figure 1D) and those derived from
subcutaneous adipose tissue (S-ASCs) by large nuclei and globular cytoplasms (Figure 1E). Both S-ASCs
and V-ASCs formed cell aggregation at the third passage (Figure 1F,G) and in low-adhesion culture
conditions formed spheres, suggesting the stem origin of the cells (Figure 1H,I).
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Figure 1. Morphology of adipose-derived stem cells (ASCs) under light microscopy (10×) with phase 
contrast with a Nikon DS-FI1 CCD camera. Scale bars: 400 µm. Stromal vascular cell fraction (SVF) 
morphological characteristics on day 2 (A), day 5 (B) and day 10 (C) of expansion cultures. Crystal 
violet staining shows visceral adipose tissue mesenchymal stem cells (V-ASCs) having large nuclei 
and extended cytoplasms (D) in comparison to subcutaneous adipose tissue mesenchymal stem cells 
(S-ASCs), which have large nuclei and globular cytoplasms (E); (F,G) show similar aggregation of 
MSCs from V-ASC and S-ASC in adhesion cultures; (H,I) show spheres from V-ASCs and S-ASCs in 
low adhesion cultures. An experiment representative of 72 samples studied is shown. 
2.2. Cell Cycle Analysis 
Cell cycle analysis at passage 3 showed no significant different distribution of cells in the G1, G2 
and S phases in S-ASC and V-ASC. S-ASC in the G1 phase was 68.10 ± 2.32% and V-ASC was  
66.01 ± 3.43%.The proliferation index (PI), expressed as % G2 + % M, was 10.3 ± 3.7% and 9.46 ± 2.14%, 
respectively, for S-ASC and V-ASC (Figure 2). 
Figure 1. Morph logy of adipose-derived stem cells (ASCs) under light microscopy (10×) with
phase contrast with a Nikon DS-FI1 CCD camera. Scale bars: 400 µm. Stromal vascular cell fraction
(SVF) morphological characteristics on day 2 (A), day 5 (B) and day 10 (C) of expansion cultures.
Crystal violet staining shows visceral adipose tissue mesenchymal stem cells (V-ASCs) having large
nuclei and extended cytoplasms (D) in comparison to subcutaneous adipose tissue mesenchymal stem
cells (S-ASCs), which have large nuclei and globular cytoplasms (E); (F,G) show similar aggregation of
MSCs from V-AS and S-ASC in dhesion cultures; (H,I) show spheres from V-ASCs and S-ASCs in
low adhesion cultures. An experiment representative of 72 samples studied is shown.
2.2. Cell Cycle Analysis
Cell cycle analysis at passage 3 showed no significant different distribution of cells in the G1,
G2 and S phases in S-ASC and V-ASC. S-ASC in the G1 phase was 68.10 ± 2.32% and V-ASC
was 66.01 ± 3.43%. The proliferation index (PI), expressed as % G2 + % M, was 10.3 ± 3.7% and
9.46 ± 2.14%, respectively, for S-ASC and V-ASC (Figure 2).
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Figure 2. Cell cycle distribution of S-ASCs and V-ASCs. Both cell types were analyzed according to 
Nicoletti’s protocol [16]. Twenty-five samples of S-ASCs and V-ASCs cultured in adhesion condition 
at passage 3 were analyzed. 
2.3. Flow Cytometry Stem Cell Phenotype Characterization 
The cell-surface antigenic characteristics of 12 samples of S-ASCs and 12 samples of V-ASCs at 
passage 3 were analyzed by flow cytometry. Both populations were positive for CD90 (94 ± 3.9% and 
91 ± 3.6%, respectively), CD105 (76 ± 4.2% and 73 ± 2.7%, respectively) and CD29 (72 ± 2.5% and  
70.8 ± 2.8%, respectively) (Figure 3A) and showed almost no expression of CD31, CD45 and CD146 
(<1%) (Figure 3B).  
 
 
Figure 2. Cell cycle distribution of S-ASC and V- SCs. Both ell types were analyzed according to
Nicoletti’s protocol [16]. Twenty-five samples of S-ASCs and V-ASCs cultured in adhesion condition at
passage 3 were analyzed.
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2.3. Flow Cytometry Stem Cell Phenotype Characterization
The cell-surface antigenic characteristics of 12 samples of S-ASCs and 12 samples of V-ASCs at
passage 3 were analyzed by flow cytometry. Both populations were positive for CD90 (94 ± 3.9% and
91 ± 3.6%, respectively), CD105 (76 ± 4.2% and 73 ± 2.7%, respectively) and CD29 (72 ± 2.5% and
70.8 ± 2.8%, respectively) (Figure 3A) and showed almost no expression of CD31, CD45 and CD146
(<1%) (Figure 3B).
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Figure 3. (A) Cytofluorimetric analysis for CD90, CD105 and CD29; (B) The cells are negative for 
CD31, CD45 and CD146 in S-ASC and V-ASC. All fields are representative of one S-ASC and V-ASC 
sample out of at least 12 independent experiments. 
2.4. Stem Cell Markers of S-ASC and V-ASC Grown as Adherent Cells or Spheres 
To assess the multipotent state of ASCs from subcutaneous and visceral adipose tissue, we 
detected some of the embryonic stem cell markers, such as ABCG2, OCT4, SOX2, C-KIT, THY1,  
CD-73, CD-105 and NANOG, using mRNA samples from 10 S-ASCs and 10 V-ASCs cultured in 
adhesion conditions. Expression analysis (see Table S1 in supplementary) showed only a significant 
difference in NANOG mRNA levels in S-ASC vs. V-ASC. ASCs from VAT and SAT expressed all of 
the examined stem cell markers (Figure 4A). 
Furthermore, we compared the stem cell transcription factor expression pattern in spheres 
derived from S-ASCs and V-ASCs vs. S-ASCs and V-ASCs in adhesion condition cultures. We found 
that NANOG, SOX2 and OCT4 were expressed at higher levels in spheres from S-ASC and V-ASC 
cells in comparison to the same cells in adhesion conditions (see Table S2 in supplementary).  
In addition, spheres from S-ASCs were characterized by the highest values, as shown in Figure 4B  
(p < 0.01). 
Figure 3. (A) Cytofluorimetric analysis for CD90, CD105 and CD29; (B) The cells are negative for CD31,
CD45 and CD146 in S-ASC and V-ASC. All fields are representative of one S-ASC and V-ASC sample
out of at least 12 independent experiments.
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2.4. Stem Cell Markers of S-ASC and V-ASC Grown as Adherent Cells or Spheres
To assess the multipotent state of ASCs from subcutaneous and visceral adipose tissue, we
detected some of the embryonic stem cell markers, such as ABCG2, OCT4, SOX2, C-KIT, THY1, CD-73,
CD-105 and NANOG, using mRNA samples from 10 S-ASCs and 10 V-ASCs cultured in adhesion
conditions. Expression analysis (see Table S1 in supplementary) showed only a significant difference
in NANOG mRNA levels in S-ASC vs. V-ASC. ASCs from VAT and SAT expressed all of the examined
stem cell markers (Figure 4A).
Furthermore, we compared the stem cell transcription factor expression pattern in spheres derived
from S-ASCs and V-ASCs vs. S-ASCs and V-ASCs in adhesion condition cultures. We found that
NANOG, SOX2 and OCT4 were expressed at higher levels in spheres from S-ASC and V-ASC cells
in comparison to the same cells in adhesion conditions (see Table S2 in supplementary). In addition,
spheres from S-ASCs were characterized by the highest values, as shown in Figure 4B (p < 0.01).Int. J. Mol. Sci. 2017, 18, 1107  6 of 17 
 
 
Figure 4. (A) qRT-PCR analyses in S-ASC and V-ASC cells cultured in adhesion condition. Data are 
representative of three independent experiments. Relative expression levels for ABCG2, OCT4, SOX2, 
CKIT, THY1, CD73, CD105 and NANOG were assessed using the 2−ΔΔCt method. Values shown as mean 
± SE, ** p < 0.01. The data shown are relative to an endogenous control (beta-actin), with the fold 
change compared to expression levels in commercial bone marrow-mesenchymal stem cells (set to 
one); (B) qRT-PCR analysis in spheres from S-ASC and V-ASC primary cells. Data are representative 
of three independent experiments with the fold change compared to expression levels in commercial 
human adipose derived stem cell (ASC52telo, hTERT immortalized adipose-derived mesenchymal 
stem cells) (set to one). Values shown as the mean ± SE, ** p < 0.01. CNT, control. 
Western blot analysis confirmed that NANOG was more expressed in ASCs isolated from SAT 
than from VAT (p < 0.01) (see Table S3 in supplementary) (Figure 5A,B). 
 
Figure 5. (A) Representative Western blot analysis in the S-ASC and V-ASC cells of NANOG, 
OCT3/4 and SOX2; (B) densitometric analysis of the Western blot depicted in (A). The histograms are 
the results of three independent experiments. The values are shown as the mean ± SE, ** p < 0.01. OD, 
optical density (** p < 0.01). 
Figure 4. (A) qRT-PCR analyses in S-ASC and V-ASC cells cultured in adhesion condition. Data are
representative of three independent experiments. Relative expression levels for ABCG2, OCT4, SOX2,
CKIT, THY1, CD73, CD105 and NANOG were assessed using the 2−∆∆Ct method. Values shown as
mean ± SE, ** p < 0.01. The data shown are relative to an endogenous control (beta-actin), with the
fold change compared to expression levels in commercial bone marrow-mesenchymal stem cells (set to
one); (B) qRT-PCR analysis in spheres from S-ASC and V-ASC primary cells. Data are representative
of three independent experiments with the fold change compared to expression levels in commercial
human adipose derived stem cell (ASC52telo, hTERT immortalized adipose-derived mesenchymal
stem cells) (set to one). Values shown as the mean ± SE, ** p < 0.01. CNT, control.
Western blot analysis confirmed that NANOG was more expressed in ASCs isolated from SAT
than from VAT (p < 0.01) (see Table S3 in supplementary) (Figure 5A,B).
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Figure 5. (A) Representative Western blot analysis in the S-ASC and V-ASC cells of NANOG, OCT3/4
and SOX2; (B) densitometric analy is of the Western blot depicted in (A). Th histograms are the re ults
of three independent experiments. Th values are s own a the mea ± SE, ** p < 0.01. OD, optical
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2.5. NANOG and SOX2 Silencing in S-ASC and V-ASC
To establish the relationship between SOX2, OCT-4, NANOG, we evaluated their expression after
NANOG silencing. NANOG silencing (Figure 6A,B) in S-ASCs after 48 h (73 ± 0.03%) and after 72 h
(70 ± 1.23%) and in V-ASCs cultured in adhesion after 48 (70 ± 1.4%) h and 72 h (72 ± 2.3%) caused
downregulation of OCT3/4 (70 ± 0.05%, p < 0.01) and SOX2 genes (75 ± 0.03%, p < 0.01) in S-ASCs
(Figure 7A,B) and in V-ASCs (Figure 7C,D).
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Figure 6. (A) NANOG silencing in S-ASCs after 48 and 72 h; (B) NANOG silencing in V-ASCs after
48 and 72 h. Fold change was calculated using the 2−∆∆Ct method. Data representative of three
independent experiments with the fold change compared to expression levels in a commercial human
adipose-derived st m cell line (ASC52telo, hTERT immortalized adipose-derived mesenchymal stem
cells). Values shown as the mean ± SE, ** p < 0.01.
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Figure 7. (A) qRT-PCR analysis in S-ASCs of the OCT4 gene after NANOG silencing; (B) qRT-PCR
analysis in S-ASCs of the SOX2 gene after NANOG silencing; (C) qRT-PCR analysis in V-ASCs of the
OCT4 gene after NANOG silencing; (D) qRT-PCR analysis in V-ASCs of the SOX2 gene after NANOG
silencing. NANOG silencing was assessed with stealth siRNA (siRNANANOG) vs. siCONTROL
treated cells (CNT). The data are representative of three independent experiments. The values are
shown as the mean ± SE, ** p < 0.01.
By contrast, SOX2 silencing after 48 h (72 ± 1.5%) and 72 h (70 ± 2.3%) (Figure 8A) in S-ASCs
cultured in adhesion showed no effect on NANOG and OCT4 expression after 48 h (Figure 8B,C).
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Western blot analysis of SOX2 and OCT3/4 after NANOG silencing with stealth siRNA after 96 h
in S-ASCs (optical density (OD) = 0.8 ± 0.1 and 0.24 ± 0.01, p < 0.01) and in V-ASCs (OD = 0.5 ± 0.01
and 0.22 ± 0.01) caused downregulation of the OCT4 protein in S-ASCs (OD = 1.16 ± 0.17 vs.
0.38 ± 0.12; p < 0.01) and in V-ASCs (OD =1.09 ± 0.16 vs. 0.39 ± 0.12, p < 0.01). At the same
time, downregulation of the SOX2 protein was observed in S-ASCs (OD: 0.49 ± 0.05 vs. 0.20 ± 0.02;
p < 0.01) and in V-ASCs (OD: 0.5 ± 0.01 vs. 0.01 ± 0.001; p < 0.01) (Figure 9).
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Figure 9. Western blot of OCT4 and SOX2 with proteins extracted from V-ASC and S-ASC cells after
NANOG silencing with stealth siRNA vs. siCONTROL treated cells.
By contrast, SOX2 silencing in S-ASC (OD = 1.3 ± 0.1 vs. 0.23 ± 0.06, p < 0.01) and in V-ASC cells
(OD = 1.16 ± 0.013 vs. 0.56 ± 0.04; p < 0.01) (Figure 10A) after 96 h was not able to affect NANOG
protein levels in S-ASC (OD = 1.17 ± 0.1 vs. 1.2 ± 0.01, p = NS) and in V-ASC (OD = 0.7 ± 0.2 vs.
0.68 ± 0.1; p = NS) (Figure 10B).
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3. Discu sion
Adipose ti sue represents an interesting source of multipotent stem ce ls [5,16] and is considered
fundamental for comprehension of adipose ti sue biology under normal physiology. In a dition,
interest in isease i also developing, even though limited information is av il ble on
visceral nd subcutaneous ASCs and the r lationship between i vitro and in vivo adipogen sis.
Int. J. Mol. Sci. 2017, 18, 1107 9 of 16
The purpose of this work was to study the different expression of the embryonic stem cell
markers NANOG, SOX2 and OCT3/4 and the role of NANOG in this network, evaluated in both
S-ASCs and V-ASCs isolated from SAT and VAT in a large series of obese and non-obese subjects, who
underwent elective open-abdominal and laparoscopy surgery. When isolated MSCs were cultured
without any substrate [17], we observed morphological differences in V-ASC and S-ASC cells, which
included cell shape and cell size in accordance with previous observations [18,19]. ASCs derived
from subcutaneous adipose tissue were characterized by large nuclei and cytoplasms and formed cell
aggregation (fusiform shape), whilst ASCs derived from visceral adipose tissue showed large nuclei
and extended cytoplasms (classical fibroblast-like). Our data confirm that cells are capable of forming
sphere clusters in a serum-free medium supplemented with fibroblast growth factor-basic (FGF-b) and
epidermal growth factor (EGF) [20], and these spheres derived from S-ASCs and V-ASCs expressed all
of the ESC markers evaluated, SOX-2, OCT4 and NANOG, more markedly than S-ASCs and V-ASCs
in adhesion, demonstrating that the spheres mostly possess stemness potential. Interestingly, during
the time of floating culture, the spheres maintained the expression of stem cell markers. From our
findings, it is possible to confirm that cultures in low adhesion conditions can be used to maintain stem
characteristics for a longer time than traditional adhesion cultures. Immunophenotyping of MSCs
derived from subcutaneous and visceral adipose tissue demonstrate that cell populations express
well-defined MSC-associated surface markers CD29, CD73, CD90 and CD105 [20,21]. Western blot
analysis confirmed the presence of stem cell markers; both ASCs were positive for SOX2, OCT3/4
and NANOG, which are the principal transcription factors that regulate pluripotency and plasticity.
Our results indicate that the stemness of ASCs should be defined by their ability to differentiate into
multiple lineages coupled with their expression of the pluripotent stem cell-related genes OCT-4,
SOX2 and NANOG. This datum could be considered useful to functionally distinguish ASCs as more
stem cell-like [22]. We found that the embryonic stem cell marker NANOG is also over-expressed in
MSCs derived from adipose tissue, confirming recent studies that have demonstrated a central role of
NANOG in embryonic stem cells [23].
Stem cell pluripotency and differentiation are strictly controlled by a coordinated network
of transcription factors [24]. Among them, OCT4 and NANOG have been recognized as crucial
transcriptional regulators of stem cell self-renewal during embryogenesis [25,26]. More recently, it has
been shown that both OCT4 and NANOG are also expressed by undifferentiated adult MSCs [27–29].
In ESCs, the over-expression of NANOG, the homeobox-containing transcription factor, is considered
fundamental in maintaining the pluripotency and self-renewing characteristics of culture conditions
inducing under-differentiation [24]. Recent studies have identified the downstream targets of OCT4,
which include genes encoding for self-renewal factors, lineage-specific factors, signaling molecules
and DNA damage response sensors [25]. Thus, OCT4 is involved in a broad spectrum of cellular
processes that collectively specify the self-renewal state of the ESCs. On the other side, the role
of SOX2 seems to be crucial, as well. Indeed, the lack of SOX2 leads ESCs to differentiation
and to the loss of pluripotency property [30]. Based on these data, NANOG is considered a core
element of the pluripotent transcriptional network. Transient downregulation of NANOG appears
to predispose cells towards differentiation, but does not mark commitment. Therefore, unlike OCT4
and SOX2, NANOG plays a pivotal role in the maintenance of the epiblast and ES cells by repressing
differentiation along the primitive endoderm lineage. SOX2 is capable of hetero-dimerizing with
OCT4 to mediate the transcription activities of several ES cell-specific genes including NANOG [31].
Interestingly, OCT4 and SOX2 are also involved in reciprocal regulation of each other’s expression [32].
OCT4 overexpression induces de-differentiation of ASCs into a more immature status by activating
the AKT/phosphoinositide 3-kinase (PI3K) and extracellular signal-related kinase (ERK1/2) signaling
pathways [33]. Indeed, it has been reported that ASCs possess their own multipotency to reprogram
into more primitive stem cells [34]. However, how this process takes place mechanistically remains
controversial. Suzuki et al showed that NANOG expression is not regulated by Brachyury T and STAT3
in mouse ESCs [35]. In human ESCs, Vallier et al. showed that activin/nodal signaling stimulates
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the expression of NANOG, which in turn prevents FGF-induced neuroectoderm differentiation [36].
In addition, several studies have demonstrated that the OCT4/SOX2 complex is directly bound to the
NANOG promoter for the target gene regulation [37]. Today, OCT4, SOX2 and NANOG are known to
bind the same regulatory regions in undifferentiated mouse and human ESCs, and these binding sites
are often in close proximity to one another [38]. These studies suggest that OCT4, SOX2 and NANOG
can physically interact with each other and coordinately regulate target genes [37,39].
In our experiments, we observed that downregulation of NANOG leads to significant
downregulation of OCT4 and SOX2, probably consistent with the loss of pluripotency. Indeed,
in previous studies, downregulation of NANOG was shown to lead to significant downregulation of
OCT4 and loss of ES/EC cell-surface antigens; upregulation of several marker genes, including GATA4,
GATA6, LAMININ B1 and AFP [30,40,41] was reported. Moreover, the trophectoderm specification is
indicated by upregulation of CDX2, GATA2, hCG-α and hCG-β [23,28,39,42,43].
All of these data confirm the use of adipose tissue as a potential source for multipotent cells
and above all propose a suitable approach for future regenerative medicine and tissue engineering
applications, as well as overall confirm its being a valuable resource in biotechnology.
4. Materials and Methods
4.1. Establishment of Adipose-Derived Stem Cell Cultures
Subcutaneous (SAT) and visceral (VAT) adipose tissue biopsies were obtained from 72 consenting
patients (23 men, 47 women; age 45 ± 10; BMI range between 25 ± 0.5 and 35 ± 5), 42 obese and
28 non-obese subjects undergoing elective open-abdominal and laparoscopy surgery. The protocol was
approved for RIMEDRI by the Independent Ethical Committee at the Azienda Ospedali Riuniti
Villa Sofia-Cervello, No. 15, 11 December 2013, Palermo, Italy. All patients gave their written
informed consent. Adipose tissue specimens were obtained from the subcutaneous and omental depots,
and approximately 1 g of adipose tissue was taken from each fat depot. All biopsies were handled
under sterile conditions and immediately used for subsequent preadipocyte isolation. Tissue specimens
were immediately transported to the clean room of the laboratory of Regenerative Medicine (ISO
14644 Ec-GMP) in DMEM/Ham’s F12 1:1, dissected from fibrous material and visible blood vessels,
cut into little fragments and incubated in PBS Ca2++/Mg++ (Phosphate-Buffered Saline with Calcium
and Mangnesium) (Sigma Chemical, St. Louis, MO, USA) supplemented with 1 mg/mL collagenase
type I (Sigma Chemical, St. Louis, MO, USA), with vigorous shaking (100 cycles/min) for 1 h at
37 ◦C. The resulting material was filtered through a 250-mm mesh, and adipocytes and free oil were
separated from stromal vascular (SVF) components by centrifugation at 1200 rpm for 5 min at room
temperature. The SVF pellet was resuspended in a growth medium consisting of DMEM/Ham’s F12
1:1 supplemented with 100 units/mL penicillin, 0.1 mg/mL streptomycin, 5% fetal calf serum (FCS),
1 ng/mL FGF-b and 10 ng/mL EGF.
4.2. Sphere Cultures
SVF cells were seeded at 1 × 102 cell/cm2 in ultra-low adherent flasks (Corning, Avon, France) in
defined culture medium, which consisted of DMEM/F12 supplemented with L-glutamine (2 mM),
nonessential amino acids (1×), B27 (1×) (Invitrogen, Milan, Italy), human FGF-b (20 ng/mL), human
EGF (20 ng/mL). Cells were incubated at 37 ◦C under 5% CO2, and half of the medium was changed
once a week. Sphere formation was assessed by counting the number of spheres (cells > 3) under an
optical microscope. To test if sphere-containing cells can revert to monolayer growth, spheres were
dissociated with accutase (Sigma Chemical) and plated in flasks treated for cell culture (TPP) in ASC
expansion medium.
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4.3. Evaluation of Morphological Characteristics
Cells were fixed for 15 min at RT in 2% (w/v) paraformaldehyde, washed twice in distilled water
and stained with crystal violet. Then, the cells were observed for their morphological features under a
Zeiss phase contrast microscope (Zeiss, Gottingen, Germany) and photographed with a Nikon camera
(Nikon, Firenze, Italy).
4.4. Flow Cytometry Analysis
Cells isolated from 12 samples of S-ASC and 12 samples of V-ASC were harvested and filtered
through a 40-µm filter mesh and suspended at the concentration of 1 × 106 cells/mL. Then, 100 µL of
cell suspension containing 5 × 105 cells were used for each flow cytometric test.
4.5. Immunophenotyping
Human anti-CD31, human anti-CD45, human anti-CD146, human anti-CD29, human anti-CD90
and human anti-CD105 (see Table 1) monoclonal antibodies were tested on S-ASC and V-ASC.
The incubation conditions were in accordance with the manufacturer’s instructions. For anti-CD90 and
anti-CD105, cells were washed twice with PBS/bovine serum albumin (BSA) 5% and incubated with
Alexa Fluor 488 goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA) antibody for 1 h in the dark.
Data were acquired on a FACS Calibur and analyzed using CELL Quest Pro software (Becton Dickinson,
Franklin Lakes, NJ, USA).
Table 1. Monoclonal antibodies used for the characterization of cell phenotypes.
Primary Antibody/Localization Marker Code Number Diluition Incubation
CD31, surface Miltenyi Biotec, 130-092-654 1:100 30 min, r.t.
CD45, surface Miltenyi Biotec, 130-080-202 1:100 30 min, r.t.
CD146, surface Miltenyi Biotec, 130-092-851 1:100 30 min, r.t.
CD90, surface Chemicon, CBL415 1:50 o/n, r.t.
CD105, surface Biolegend,323202 1:50 o/n, r.t.
CD29, surface Miltenyi Biotec, 130-101-256 1:100 30 min, r.t.
Secondary antibody Code Number Diluition Incubation
AlexaFluor 488 Life Technologies, Z25402 1:50 20 min, r.t.
Miltenyi Biotec, Bergisch Gladbach, Germany; Santa Cruz, Dallas, Texas; BioLegend, London, UK; Life Technologies,
Carlsbad, CA, USA; o/n, overnight; r.t., room temperature.
4.6. Analysis of Cell Cycle Status of MSCs
Single-cell suspensions of 25 samples of S-ASC and 25 samples of V-ASC were obtained and
seeded at a density of 2 × 103 cells/cm2 (passage 3), and the DNA content was assessed according
to Nicoletti’s protocol. Briefly, 1 × 106 cells were fixed in 70% ethanol, rehydrated in PBS and
then re-suspended in a DNA extraction buffer (with 0.2 M NaHPO4, 0.1% Tritonx-100 and, pH 7.8).
Cells were stained with 1 µg/mL of propidium iodide (PI) for 5 min; fluorescence intensity was
determined by analysis on a FACS Calibur (Becton Dickinson). Data were acquired with CellQuest Pro
software (Becton Dickinson) software, and the percentages of G1, S and G2 phase cells were calculated
with the MODFIT-LT 5.0 software program (Verity Software House Inc., Topsham, ME, USA).
4.7. RNA Isolation and Quantitative RT-PCR
mRNA from ASCs populations isolated from VAT and SAT biopsies derived from obese and
normal weight patients were isolated using an RNeasy kit (Qiagen, Hamburg, Germany). Two hundred
fifty nanograms of RNA from S-ASC and V-ASC were reverse-transcribed with standard reagents
(Promega, Madison, WI, USA). One microliter of each reverse-transcription reaction was amplified
using SYBR Green PCR master mix from Qiagen (Quantitect SYBR green master mix), using the
RotorGene PCR system (Qiagen, Hamburg, Germany). For each gene, mRNA expression was
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normalized for the housekeeping gene β-actin. Amplification of specific transcripts was confirmed by
melting curve profiles at the end of each PCR. PCR primers, OCT4, NANOG, THY-1 (CD-90), CD105
and CD 73 were purchased from Qiagen (QuantiTect® Primer Assays, Qiagen); primer for SOX2
was purchased from MWG (Eurofins Genomics, Ebersberg, Germany); and primer for β-actin was
purchased from Invitrogen (Table 2) All reactions were performed using the Quantitect SYBR Green
PCR Kit (Qiagen) on the RotorGene Q Instrument (Qiagen). Each cDNA sample was mixed with
specific primer sets and PCR master mix. The PCR reactions were performed using the following
parameters for 40 cycles: denaturation at 95 ◦C for 3 min, 95 ◦C for 20 s, annealing at 60 ◦C for 30 s
and elongation at 72 ◦C for 60 s. Reactions were performed at least in triplicate. The specificity
of the amplified products was determined by melting peak analysis. The relative quantification
model with efficiency correction was applied to normalize the expression of the target gene to β-actin
(used as a housekeeping gene) and to compare gene expression with bone marrow mesenchymal stem
cell(BM-MSCs) and with a commercial primary cell line immortalized with a human telomerase reverse
transcriptase (hTERT) immortalized cell lines (ASC52telo, hTERT immortalized adipose-derived
mesenchymal stem cells (ATCC® SCRC-4000™, American Type Culture Collection, Manassas, VA,
USA), used as a positive cell control. Relative expression levels for ABCG2, OCT4, SOX2, CKIT, THY1,
CD73, CD105 and NANOG were assessed using the 2−∆∆Ct method. The results were represented
as histograms with GraphPad Prism 6 Software (GraphPad Software, Inc. La Jolla, CA, USA).
The qRT-PCR analyses for the stem gene were also performed after siRNA transfection experiments.
Table 2. Real-time quantitative PCR primers used for gene expression investigation.











′-GGACTT CGA GCA AGA GAT GG-3′
REVERSE: 5′-AGC ACT GTG TTG GCG TAC AG-3′
4.8. siRNA Transfection
siRNAs transfection in 10 samples of S-ASC and in 10 sample of V-ASC was performed
using the INTERFERin TM transfection agent (Polyplus-Transfection, Illkirch, France), according
to the manufacturer’s instructions. Briefly, cells were seeded into six-well plates at a density of
250,000 cells/well or 96-well plates at a density of 3000 cells/well. The transfection agent and the
siRNA complex were added to the cells and incubated for 72 h for expression analysis and 96 h for
protein detection. The final concentration of SOX2 siRNA was 100 nM for mRNA analysis, 150 nM for
protein detection and 40 nM for NANOG siRNA. Each assay was performed in triplicate in at least
three independent experiments. SOX2 was silenced using Stealth siRNA SOX2 HSS144045 (Invitrogen).
siCONTROL Stealth siRNA Negative Control was used as a control (Invitrogen). NANOG was silenced
by NANOG siRNA (Santa Cruz Biotechnology, Dallas, TX, USA), and control siRNAs were used as a
no-target control (Santa Cruz Biotechnology).
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4.9. Western Blot Analysis
Proteins were extracted from adherent cultured cells isolated from 5 samples of S-ASC and
5 samples of V-ASC using RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet
P40), supplemented with a protease inhibitor cocktail (Complete mini, Roche Diagnostics GmbH,
Mannheim, Germany) and phosphatase inhibitors. Protein content was determined according to
Bradford’s method. Proteins were separated by Bio-Rad (Bio-Rad, Segrate, Italy), electrotransferred
to nitrocellulose membrane and blotted with the following primary antibodies: rabbit
antihuman SOX2 (Poly6308, BioLegend, San Diego, CA, USA), mouse antihuman Oct-4 (sc-5279,
Santa Cruz Biotechnology), goat antihuman NANOG (sc-30331, Santa Cruz Biotechnology), mouse
anti-β-actin IgG1 (A5441, Sigma-Aldrich) Secondary antibodies were goat anti-rabbit IgG-HRP (sc-2030,
Santa Cruz Biotechnology), goat anti-mouse IgG-HRP (sc-2031, Santa Cruz Biotechnology) and donkey
anti-goat IgG-HRP (sc-2033, Santa Cruz Biotechnology) (see Table 3). Antigen-antibody complexes
were visualized using the ECL prime (Amersham, GE Healthcare Europe GmbH, Milan, Italy) on a
CCD camera (Chemidoc, Bio-Rad, Milan, Italy). Western blot bands were quantified with ImageJ 1.48
software (National Institutes of Health, Bethesda, MD, USA).
Table 3. Antibodies used for characterization for stem cell markers.
Primary Antibody/Localization Marker Code Number Dilution Incubation
NANOG, nuclear and cytoplasmatic sc-30331, Santa Cruz Biotechnology 1:500 o/n, 4 ◦C
OCT3/4, nuclear sc-5279 , Santa Cruz Biotechnology 1:500 o/n, 4 ◦C
SOX2 nuclear Poly6308, BioLegend 1:500 o/n, 4 ◦C
Secondary Antibody Code Number Diluition Incubation
Goat anti-rabbit IgG-HRP sc-2030, Santa Cruz Biotechnology 1:2500 90 min, r.t.
Goat anti-mouse IgG-HRP sc-2031, Santa Cruz Biotechnology 1:2500 90 min, r.t.
Donkey anti-goat IgG-HRP sc-2033, Santa Cruz Biotechnology 1:2500 90 min, r.t.
Santa Cruz Biotechnology, Dallas, Texas; BioLegend, San Diego, CA; o/n, overnight; r.t., room temperature.
5. Conclusions
The use of adipose-derived stem cell is promising in regenerative medicine and tissue engineering
applications and constitutes a valuable resource in biotechnology. Our aim was to study the different
expression of embryonic stem cell markers NANOG, SOX2 and OCT3/4 in ASCs derived from SAT
and VAT tissue and to explore whether NANOG possesses a more prominent role in this network.
Our experiments confirm the presence of the principal transcription factors that regulate pluripotency
and plasticity in both S-ASC and V-ASC cells. In spheres, SOX2, OCT4 and NANOG genes were
highly expressed when compared with adherent S-ASC and V-ASC cells. From our findings, NANOG
seems to exert a hierarchical role in the network that regulates pluripotency, as its silencing causes
downregulation of OCT3/4 and SOX2 genes in both S-ASCs and V-ASCs, while SOX2 silencing does
not affect NANOG and OCT3/4 gene expression in both S-ASCs and V-ASCs. In the future, other
methods will be necessary to further investigate whether NANOG downregulation in S-ASC and
in V-ASC cells plays a role in the long-term differentiation of specialized cells. Finally, the lack of
OCT4 silencing represents a limit for the definition of the single role of each network component.
In conclusion, our results outline the importance of these data for future applications of ASC cells in
regenerative medicine.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/6/1107/s1.
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